亚太药业(002370) - 2015 Q3 - 季度财报

Financial Performance - Operating revenue for the period reached CNY 98,984,230.06, representing a 20.81% increase year-on-year[6] - Net profit attributable to shareholders increased by 112.07% to CNY 11,554,485.37 for the period[6] - The net profit excluding non-recurring gains and losses rose by 105.38% to CNY 11,674,996.33[6] - Basic earnings per share doubled to CNY 0.06, a 100% increase compared to the same period last year[6] - The expected net profit for 2015 is not a turnaround situation, indicating consistent operational performance[19] - Net profit for the period was ¥11,554,485.37, representing a significant increase of 111.5% from ¥5,448,526.18 in the previous year[35] - Net profit for the current period was ¥43,120,107.60, representing a 54.1% increase compared to ¥27,980,144.13 in the previous period[43] - Total comprehensive income for the current period was ¥43,517,384.34, compared to ¥29,187,553.82 in the previous period, reflecting a growth of 49.2%[43] Assets and Liabilities - Total assets increased by 6.12% to CNY 900,485,821.53 compared to the end of the previous year[6] - Total liabilities amounted to CNY 130,053,772.79, up from CNY 101,212,797.97, indicating an increase of about 28.5%[28] - Current assets totaled CNY 534,722,715.41, an increase from CNY 493,646,927.34, reflecting a growth of about 8.5%[26] - Total non-current assets were CNY 365,763,106.12, an increase from CNY 354,880,535.03, reflecting a growth of approximately 3.9%[27] - Total liabilities increased to ¥129,673,491.84 from ¥99,541,335.92, indicating a rise of 30.3% year-over-year[35] - The company's equity attributable to shareholders reached CNY 770,432,048.74, compared to CNY 747,314,664.40, reflecting an increase of approximately 3.1%[29] Cash Flow - Cash flow from operating activities decreased by 23.03% to CNY 31,111,429.52 year-to-date[6] - The net cash flow from operating activities for Q3 2015 was ¥31,111,429.52, a decrease of 23% compared to ¥40,421,601.21 in Q3 2014[50] - Total cash inflow from operating activities was ¥272,806,760.46, up 58.5% from ¥172,137,688.77 in the same period last year[50] - Cash outflow from operating activities increased to ¥241,695,330.94, compared to ¥131,716,087.56 in Q3 2014, representing an increase of 83.5%[50] - The net cash flow from investing activities was -¥24,847,854.78, a significant improvement from -¥68,887,089.22 in the previous year[51] - The ending balance of cash and cash equivalents was ¥210,874,334.21, slightly down from ¥207,765,320.08 in Q3 2014[51] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 204,000,000[9] - The largest shareholder, Zhejiang Apac Group Co., Ltd., holds 35.20% of the shares, amounting to 71,800,000 shares[9] - The company has committed to not reduce its holdings in the company from July 9, 2015, to December 31, 2015, ensuring stability for minority shareholders[18] Strategic Initiatives - The company attributes the performance improvement to the continuous optimization of the sales system and market channels, leading to increased revenue from specialty products[19] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[35] - The company is focused on avoiding competition with its controlling shareholder, ensuring that no similar business activities are conducted by related entities[17] Stock and Trading Information - The stock of Zhejiang Apac Pharmaceutical Co., Ltd. was temporarily suspended from trading on April 28, 2015, due to major asset restructuring plans[14] - The company announced a non-public stock issuance plan and a major asset purchase report on October 10, 2015, which was approved by the board[15] - The company’s stock resumed trading on October 21, 2015, following the completion of necessary approvals for the asset restructuring[15] Expenses - Total operating costs amounted to ¥85,210,679.52, up from ¥75,344,748.17, reflecting a year-over-year increase of 13.4%[34] - The company’s sales expenses increased to ¥44,020,813.74 from ¥36,451,273.11, indicating a rise of 20.5%[42] - Management expenses also rose to ¥40,595,095.62 from ¥35,338,026.49, an increase of 15.9%[42]